CA-TALKDESK,-INC.
23.3.2022 11:02:03 CET | Business Wire | Press release
Talkdesk®, Inc. , a global customer experience leader for customer-obsessed companies, has been selected by Palma-based travel icon Iberostar Hotels & Resorts as its contact center solution provider. Talkdesk ensured a successful journey for Iberostar as the company navigated from on premises to remote call center operations.
As with many companies in the hospitality industry, COVID-19 became a catalyst for Iberostar Hotel & Resorts’ contact center modernization. Pre-pandemic, the hotel chain’s reservation center agents worked exclusively on premises, on desktops. COVID-19 restrictions meant that agents would need to work from home, immediately and indefinitely. Additionally, worldwide travel disruptions led to unprecedented call volumes. While Iberostar Hotels & Resorts quickly pivoted reservation center operations to a remote model, the company recognized the need for a more advanced, flexible technology to support immediate requirements, as well as long-term goals.
Talkdesk CX Cloud™ , an end-to-end customer experience solution, allowed Iberostar Hotels & Resorts to create a single virtual reservation center. Advanced routing capabilities helped their agents better manage fluctuating call volumes, and deep integration with Salesforce™ enabled agents to provide a more personalized experience for every guest. The Talkdesk solution empowered Iberostar Hotel & Resorts agents to continue providing the company’s signature global standard setting customer service no matter where they were working from.
“One of Iberostar Hotel & Resorts' greatest strengths is our commitment to quality. For us, customers aren’t just guests, they’re an extension of our family and we’re dedicated to providing the best holiday experience for them from start to finish,” said Lucía Rubio, contact centers and CX online director, Iberostar Hotels & Resorts. “With the Talkdesk solution, no matter where our agents are working, they have the tools they need to make guests feel valued and welcomed in every interaction.”
“As global travel starts a return to pre-pandemic volume, competition for guest loyalty will be even greater. Travelers will look to re-engage with the brands they trust most, and customer experience is essential to building and nurturing that trust,” said Kieran King, chief customer officer, Talkdesk. “With a modernized virtual contact center solution, Iberostar Hotels & Resorts empowers their agents to support the kind of holiday experience guests deserve, from the very first contact onwards. Talkdesk is proud to partner with them in achieving their customer experience goals.”
Additional Resources
- See Talkdesk recognized as a Leader in the Gartner 2020 Magic Quadrant for Contact Center as a Service
- Hear from customers about why they selected Talkdesk CX Cloud and the difference it has made in their contact centers
Social Networks
- Web: https://www.talkdesk.com/customer-community/
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global cloud contact center leader for customer-obsessed companies. Our automation-first customer experience solutions optimize our customers’ most critical customer service processes. Our speed of innovation, vertical expertise, and global footprint reflect our commitment to ensuring that businesses can deliver better experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
